Current opinion in HIV and AIDS · 2026
Mpox therapeutics in the post-STOMP/PALM era.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Promer Katherine, Brenner Sara Bt, Ostrer Lily, Bortner Adam C, Wilkin Timothy J
Аннотация
PURPOSE OF REVIEW: This article reviews the evidence behind mpox antiviral therapies which are clinically available and/or or under clinical investigation. For much of the mpox epidemic, tecovirimat has been used compassionately but there is no evidence of its clinical efficacy.
RECENT FINDINGS: Multiple phase 3 placebo-controlled trials have failed to demonstrate clinical efficacy of tecovirimat in the treatment of mpox.
SUMMARY: This article summarizes the evidence behind current treatment recommendations including tecovirimat, brincidofovir, cidofovir, trifluridine, and VIGIV, as well as other investigational treatments.
RECENT FINDINGS: Multiple phase 3 placebo-controlled trials have failed to demonstrate clinical efficacy of tecovirimat in the treatment of mpox.
SUMMARY: This article summarizes the evidence behind current treatment recommendations including tecovirimat, brincidofovir, cidofovir, trifluridine, and VIGIV, as well as other investigational treatments.